GenoSpectra Appoints Dr. Frank Witney Chief Executive Officer; Discovery Tools Executive to Drive Commercialization of Massively Parallel Assay Technology.Business Editors and Health/Medical Writers NOTE TO MEDIA: Multimedia assets available BIOWIRE2K FREMONT, Calif.--(BUSINESS WIRE)--July 30, 2002 GenoSpectra, Inc. today announced that Frank Witney, Ph.D. has been appointed to the newly created position of chief executive officer. Dr. Witney, who was most recently president, Drug Discovery Tools at PerkinElmer Life Sciences, joins GenoSpectra as the company moves forward to commercialize its massively parallel See MPP. assay technology for genomics, proteomics and high-throughput screening High-throughput screening (HTS), is a method for scientific experimentation especially used in drug discovery and relevant to the fields of biology and chemistry. Purpose and method . Dr. Witney will refine the commercialization strategy for GenoSpectra's proprietary fiber optics-enabled technology platform and oversee the development of infrastructure to support the company's growth plans. Dr. Witney brings nineteen years of life science industry experience to GenoSpectra, including eight years of executive-level operational leadership and nine years of commercial product development management. Prior to his position at PerkinElmer, he served as President and Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. of Packard BioScience. During his tenure at Packard, the company achieved rapid growth in revenues and operating profits. Previously, Dr. Witney served as Group Operations Manager See datacenter manager. of the Life Science Group at Bio-Rad Laboratories, where he led the company's efforts in entering the rapidly growing markets for proteomic and bioassay Bioassay A method for the quantitation of the effects on a biological system by its exposure to a substance, as well as the quantitation of the concentration of a substance by some observable effect on a biological system. technologies. Dr. Witney holds a doctorate in molecular and cell biology Cell biology The study of the activities, functions, properties, and structures of cells. Cells were discovered in the middle of the seventeenth century after the microscope was invented. from Indiana University Indiana University, main campus at Bloomington; state supported; coeducational; chartered 1820 as a seminary, opened 1824. It became a college in 1828 and a university in 1838. The medical center (run jointly with Purdue Univ. . "Frank brings a unique combination of successful operational experience, scientific depth and insight, and industry-specific market knowledge to GenoSpectra," said Alan Frazier, chairman of the Board, GenoSpectra. "GenoSpectra has exceeded expectations in meeting technology and product development milestones, and the company will now benefit from Frank's strong product and business development leadership experience as we move into a commercialization phase." "GenoSpectra has created a remarkable system that allows simultaneous transfer of information and materials using the massively parallel processing power of fiber optics fiber optics, transmission of digitized messages or information by light pulses along hair-thin glass fibers. Each fiber is surrounded by a cladding having a high index of refractance so that the light is internally reflected and travels the length of the fiber ," said Dr. Witney. "This technological innovation holds the promise of eliminating a number of bottlenecks currently impacting the drug discovery processes. The levels of throughput and efficiency made possible by GenoSpectra's technology will bring radical changes to this market." "GenoSpectra is making rapid and admirable progress in developing its unique, massively parallel approach to drug discovery research," said Dr. Alejandro Zaffaroni, renowned biotechnology pioneer and the founding investor of GenoSpectra. "Frank's solid management experience with leading life science technology companies and vision for this industry will be a great asset to GenoSpectra as it continues to develop its commercialization strategy." GenoSpectra, Inc., a privately held life science company, is applying its proprietary fiber optics-enabled technology to develop a massively parallel processing platform and products for drug discovery. The company was founded in April 2000 and is based in Fremont, Calif. For more information, please visit www.genospectra.com. Note to Editors: GenoSpectra and the GenoSpectra logo are trademarks of GenoSpectra, Inc. Note: A Photo is available at URL URL in full Uniform Resource Locator Address of a resource on the Internet. The resource can be any type of file stored on a server, such as a Web page, a text file, a graphics file, or an application program. : http://www.businesswire.com/cgi-bin/photo.cgi?pw.073002/bb4 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion